Literature DB >> 21370912

Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA.

Filipa Mendes1, Michael Groessl, Alexey A Nazarov, Yury O Tsybin, Gianni Sava, Isabel Santos, Paul J Dyson, Angela Casini.   

Abstract

The inhibition activity of a series of anticancer metal complexes based on platinum, ruthenium, and gold metal ions was evaluated on the zinc-finger protein PARP-1, either purified or directly on protein extracts from human breast cancer MCF7 cells. Information on the reactivity of the metal complexes with the PARP-1 zinc-finger domain was obtained by high-resolution ESI FT-ICR mass spectrometry. An excellent correlation between PARP-1 inhibition in protein extracts and the ability of the complexes to bind to the zinc-finger motif (in competition with zinc) was established. The results support a model whereby displacement of zinc from the PARP-1 zinc finger by other metal ions leads to decreased PARP-1 activity. In vitro combination studies of cisplatin with NAMI-A and RAPTA-T on different cancer cell lines (MCF7, A2780, and A2780cisR) showed that, in some cases, a synergistic effect is in operation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21370912     DOI: 10.1021/jm2000135

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

Review 1.  Natural inhibitors of poly(ADP-ribose) polymerase-1.

Authors:  Marek Banasik; Todd Stedeford; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2012-04-04       Impact factor: 5.590

2.  Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c.).

Authors:  Luigi Messori; Maria Agostina Cinellu; Antonello Merlino
Journal:  ACS Med Chem Lett       Date:  2014-07-31       Impact factor: 4.345

3.  Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.

Authors:  Alberta Bergamo; Tina Riedel; Paul J Dyson; Gianni Sava
Journal:  Invest New Drugs       Date:  2014-10-23       Impact factor: 3.850

4.  Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis.

Authors:  Rui Liu; Ping Ji; Bin Liu; Haishi Qiao; Xia Wang; Likun Zhou; Ting Deng; Yi Ba
Journal:  Oncol Lett       Date:  2016-12-14       Impact factor: 2.967

5.  Gold ion-angiotensin peptide interaction by mass spectrometry.

Authors:  Jenny Lee; Lasanthi P Jayathilaka; Shalini Gupta; Jin-Sheng Huang; Bao-Shiang Lee
Journal:  J Am Soc Mass Spectrom       Date:  2012-02-17       Impact factor: 3.109

6.  Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.

Authors:  Malgorzata Frik; Josefina Jiménez; Vadim Vasilevski; Monica Carreira; Andreia de Almeida; Elena Gascón; Farrah Benoit; Mercedes Sanaú; Angela Casini; María Contel
Journal:  Inorg Chem Front       Date:  2014-03-07       Impact factor: 6.569

7.  Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.

Authors:  Nicholas Lease; Vadim Vasilevski; Monica Carreira; Andreia de Almeida; Mercedes Sanaú; Pipsa Hirva; Angela Casini; María Contel
Journal:  J Med Chem       Date:  2013-07-02       Impact factor: 7.446

8.  Arsenite Exposure Displaces Zinc from ZRANB2 Leading to Altered Splicing.

Authors:  Mayukh Banerjee; Ana P Ferragut Cardoso; Angeliki Lykoudi; Daniel W Wilkey; Jianmin Pan; Walter H Watson; Nichola C Garbett; Shesh N Rai; Michael L Merchant; J Christopher States
Journal:  Chem Res Toxicol       Date:  2020-04-27       Impact factor: 3.739

Review 9.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

10.  Metals and breast cancer: risk factors or healing agents?

Authors:  Ana-Maria Florea; Dietrich Büsselberg
Journal:  J Toxicol       Date:  2011-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.